Adapted01 Breast Cancer

Oncotype DX (ODX) is a commercially available genetic profiling test that predicts recurrence risk and benefits of addition of chemotherapy for ER+, HER2-, lymph-node negative breast cancer patients; ODX evaluates expression of 21 genes and calculates a recurrence score (RS) from 0-100, with higher scores indicating greater likelihood of recurrence based on TAILORx clinical trial results. TAILORx trial shows that in patients with a high RS (26-100), the administration of adjuvant chemotherapy significantly reduces cancer recurrence and mortality, while patients with a low RS (0-25) receive no additional benefit from chemotherapeutic treatment. While performance of ODX gives personalized prognostic and predictive information for individual breast cancer patients, this test is expensive with high costs for patient and healthcare system. A decision support system, called ADAPTED01, was designed in a retrospective study to predict RS ≤25 and adequately select requests of ODX based on quantitative immunochemistry analysis [estrogen receptor (ER), progesterone receptor (PR), proliferation indices (Ki-67)].

Oncotype DX (ODX) is a commercially available genetic profiling test that predicts recurrence risk and benefits of addition of chemotherapy for ER+, HER2-, lymph-node negative breast cancer patients; ODX evaluates expression of 21 genes and calculates a recurrence score (RS) from 0-100, with higher scores indicating greater likelihood of recurrence based on TAILORx clinical trial results. TAILORx trial shows that in patients with a high RS (26-100), the administration of adjuvant chemotherapy significantly reduces cancer recurrence and mortality, while patients with a low RS (0-25) receive no additional benefit from chemotherapeutic treatment. While performance of ODX gives personalized prognostic and predictive information for individual breast cancer patients, this test is expensive with high costs for patient and healthcare system. A decision support system, called ADAPTED01, was designed in a retrospective study to predict RS ≤25 and adequately select requests of ODX based on quantitative immunochemistry analysis [estrogen receptor (ER), progesterone receptor (PR), proliferation indices (Ki-67)].